A shot offering protection against a common childhood disease was one of the 20th century’s major public health advances. For the author’s young sister, it came too late.
â Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron s Microneedle-Based Measles-Rubella Vaccine â
ATLANTA, July 13, 2021 /PRNewswire/ - Micron Biomedical, Inc. ( Micron or the Company ), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella ( MR ) vaccine.
The trial will assess the safety, tolerability and immunogenicity of an MR vaccine delivered using Micron s technology, compared with delivery via standard subcutaneous injection, in adults and children. The Company-sponsored Phase 1/2 trial will be conducted at the Medical Research Council Unit The Gambia ( MRCG ) under the leadership of Ed Clarke, MB ChB PhD, Head of Infant Immunology at the London School of Hygiene and Tropical Medicine ( LSHTM ) in The Gambia.
Micron Biomedical Initiates First-Ever Microneedle Vaccine Clinical Trial in Children apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.